Fresenius Kabi

A highlight from Fresenius Kabi Symposium at the 46th ESPEN Congress in Milan! 🎥 Some key statements from our speakers, distinguished nutrition experts, on the vital role of nutrition in cancer care: 🇵🇱 Prof. Stanislaw Klek from Poland emphasized that successful cancer treatment of malnourished patients is impossible without addressing nutrition. 🇮🇹 Prof. Isacco Montroni from Italy reminded us that proper nutrition is key to ensuring successful surgeries. 🇲🇽 Dr. Vanessa Fuchs from Mexico highlighted the importance of timely intervention and continuous monitoring 🇬🇧 Prof. Simon Lal from UK stressed the need for personalized care through a multidisciplinary approach. The key takeaway: Nutrition matters—early, individualized, and comprehensive intervention is essential for better cancer outcomes. Stay tuned for the full expert interviews and a graphical abstract of the session, coming soon on nutrionevents.com! #ESPEN2024 #ClinicalNutrition #CommittedToLife

Breast cancer is one of the most common cancers affecting women worldwide. But there’s good news: Early detection through regular screenings can greatly increase the chances of successful treatment. 💪 Regular self-examinations and annual check-ups with your doctor are crucial in the fight against breast cancer. Together, we can spread awareness and encourage women everywhere to prioritize their health. 🎗️ Our dear colleagues at Helios Kliniken GmbH and Quirónsalud offer early detection screenings and provide tips on how you can identify breast cancer at an early stage yourself. Join us this Breast Cancer Awareness Month in raising awareness and supporting those affected by breast cancer. At Fresenius Kabi, this is especially important to us as we contribute to the care of breast cancer patients through our therapies and support programs. 💖 #EarlyDetectionSavesLives #CommittedToLife

Exciting news! 🎉 Dr. Sandra Emily Stoll, Senior Physician at the University Hospital Cologne, Germany, is the recipient of our 2024 Clinical Nutrition Research Award, granted in collaboration with the European Society of Intensive Care Medicine (ESICM). Dr. Stoll’s research, titled “Impact of Cyclic Enteral Daytime Feeding with Ketogenic Nighttime Fasting on Postoperative Delirium in Critically Ill Patients (DeliKet-Study),” has been recognized with a €20,000 grant to support her important work. Through initiatives like this, we continue to advance the science of clinical nutrition and improve outcomes for critically ill patients. We are honored to support cutting-edge research and enable medical professionals to deliver the highest-quality care. 📅 The award was announced at the LIVES 2024 European Society of Intensive Care Medicine - ESICM Congress in Barcelona, where over 5,000 healthcare professionals gathered to explore the latest advances in intensive care. We are also excited to sponsor three clinical fellowships in Belgium, Germany, and Sweden, providing hands-on training in critical care nutrition. #ESICM24 #ClinicalNutrition #CommittedToLife

We are excited to be part of the 32nd United European Gastroenterology Week (UEG) in Vienna, Austria, from October 12-15, 2024! Join us to discover the future of gastroenterology. 🩺 📅 We are also hosting a symposium and would love to see you there: "Difficult-To-Treat Crohn’s Disease. From Monotherapy to Dual Targeted Therapy: Towards a New Paradigm?" on October 14 at 5:30 p.m. CEST, chaired by Prof. Laurent Peyrin-Biroulet (France) and featuring expert insights from Prof. Edouard Louis (Belgium) and Prof. Vipul Jairath (Canada). We look forward to connecting with you in Vienna and exploring our biosimilars portfolio! #UEGweek #Gastroenterology #Biopharma #CommmittedToLife UEG - United European Gastroenterology

Supporting breast cancer patients is essential in the fight against a disease that affects millions of lives worldwide. Every patient deserves access to affordable, high-quality treatments that offer hope and a path to recovery. Through a range of oncology therapies, we are committed to making life-saving treatments more accessible and affordable. These options are critical for healthcare professionals as they work tirelessly to provide the best possible care for patients battling breast cancer. Across the Fresenius family, this mission is shared by our colleagues from Helios and Quirónsalud, two of Europe’s leading healthcare providers. Both are deeply dedicated to raising awareness, improving early detection, and offering personalized, cutting-edge treatments. Together, we are helping to ensure that patients and their caregivers have the resources and support they need during every stage of their journey. Join us throughout October as we raise awareness and support those impacted by breast cancer. Discover the thoughtful and remarkable activities our colleagues around the world are engaging in to highlight this important cause. Together, we can make a difference for patients, healthcare professionals, and families everywhere. 🎗️💪 #BreastCancerAwareness #CommittedToLife

mAbxience, a Fresenius Kabi majority-owned group, and Teva Pharmaceuticals entered a second global licensing agreement for the development of an oncology biosimilar candidate. Great news and clear indicator of our shared commitment to making high-quality, affordable treatments accessible to patients worldwide in line with #FutureFresenius. Read more here: https://lnkd.in/eDJNezag #Biopharma #CommittedToLife

We welcome Molly Benson in her new role as Senior Vice President of Region US Biopharma at Fresenius Kabi. With Molly’s appointment, we are continuing our path of transformation to further develop the innovative strength of our Biopharma business in the US. #Vision2026 #FutureFresenius #TeamFresenius #CommittedToLife

📚 School start: A lesson in empathy and understanding 📚 As children with special medical needs start school, they often face challenges that many of us might never experience. They enter an unfamiliar environment where their classmates may not be aware of the complexities they navigate daily. This year, we were inspired by the courage of Leo, the son of one of our colleagues, who has been receiving home parenteral nutrition since his early days. Accompanied by his cuddly toy, Leo turned his new experience into an educational opportunity. He explained to his classmates why he uses a wheeled suitcase instead of a backpack and the importance of being careful around his catheter. Since the catheter is placed between his chest and his shoulder, wearing a traditional backpack would be too risky. Without the suitcase, he would have to carry a backpack with his hands all day long. With the help of his toy monkey and a demo catheter, Leo shared his story and explained how his parenteral nutrition works, making it easier for his peers to understand and support him. Stories like these highlight the incredible resilience of children and remind us of the supportive role we can all play in embracing and understanding differences. We would love to hear how you or someone you know explains their parenteral nutrition needs. Comment below to share your story and inspire others! #MedicalNutrition #ParenteralNutrition #CommittedToLife

BREAKING: The FDA has approved our fourth biosimilar. Our Ustekinumab biosimilar, in partnership with Formycon AG, is indicated for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis in adult patients, moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy, and active psoriatic arthritis in patients 6 years and older. It is contraindicated in patients with significant hypersensitivity to Ustekinumab products or to any of its excipients.    “This milestone approval of our fourth biosimilar will enhance the accessibility of high-quality, affordable biologic treatments for both patients and healthcare providers in the U.S.,” said Arunesh Verma, President, Fresenius Kabi USA. “We’re pleased to continue our efforts to support broader access to essential biologics and contribute to a more sustainable healthcare system.”    Read the news release: https://lnkd.in/e3fhQJMD     Please see Important Safety Information for Ustekinumab-aauz at  https://lnkd.in/eNWd7Nj3.   #FDAappoved #Biosimilars #FutureFresenius #CommittedToLife

On today’s World Heart Day, we honor the tireless efforts of healthcare professionals who stand on the frontlines of cardiac care, making life-saving decisions every day. With heart disease continuing to be the leading cause of death globally, access to effective, high-quality treatments is more critical than ever. At Fresenius Kabi, we are committed to supporting healthcare professionals in providing the best possible care for patients. From managing arrhythmias to improving cardiac output, our portfolio of affordable generics helps to ensure that essential treatments are always within reach – empowering healthcare systems to deliver better outcomes, even in the most challenging situations. Together, we can continue to make a difference, one heartbeat at a time. ❤️ #CardiacCare #Pharma #CommittedToLife